Company Overview and News

 
A day of giving by children, for children

2018-10-04 businesstimes.com.sg
CHILDREN'S Day celebrations came a little earlier this year for 1,000 children treated to a jaunt on Thursday to The Maritime Experiential Museum, S.E.A Aquarium and a live musical performance, as part of the Children for Children initiative. Children's Day falls on Oct 5 this year.
C09 CDEVF CDEVY S41

 
DBS is first Southeast Asia bank in Dow Jones Sustainability Index Asia Pacific

2018-10-02 theedgemarkets
SINGAPORE (Oct 2): DBS is the first bank in Southeast Asia and one of five Singapore-listed companies to be included in the Dow Jones Sustainability Index (DJSI) Asia Pacific.
GARPY E5H GARPF C09 CDEVF CDEVY

 
STI rebounds 1.8%, Vividthree debuts and buybacks tally declines

2018-09-30 businesstimes.com.sg
FOR the five trading sessions ended Sep 27, the Straits Times Index (STI) climbed 1.8 per cent, with the Nikkei 225, Hang Seng and S&P/ASX 200 Indices averaging a 0.3 per cent gain.
C9Q 5UX SLVFF B73 BLH CDEVY O39 U10 5IC C09 L23 K2LU 5CP CDEVF E6R

2
Millennium & Copthorne Hotels chief leaves after just three months in charge

2018-09-28 channelnewsasia
REUTERS: The chief executive of Britain's Millennium & Copthorne Hotels (M&C) has stepped down after only three months in the top job, leaving with a payoff in excess of one million pounds (US$1.3 million).
IHG ICHGF C09 IHG CDEVF LNSTY CDEVY

 
Chinese real estate services firm E-House seeks up to US$727 million in Hong Kong IPO

2018-09-26 scmp
E-House (China) Enterprise Holdings, one of the country’s biggest real estate services firms, is seeking up to US$727 million in its initial public offering in Hong Kong after delisting from New York two years ago.
C09 CDEVF DTK CDEVY 0012

 
CapitaLand Bouncing Back On Renewed Asset Recycling

2018-09-25 seekingalpha
CapitaLand has stepped up its asset recycling efforts, including a sizable investment into U.S. West Coast multi-family housing.
U14 C09 UOLGF WKSGY CDEVF UOLGY CDEVY CLLDY

 
Debt is not the problem; sustainability is

2018-09-21 theedgemarkets
SINGAPORE (Sept 21): There were at least 102 Singapore-listed companies with net gearing ratios of above 100%, with 17 operating in the property management and development industry, according to 12-month trailing data from Bloomberg.
c29 CHSEF C09 CDEVF CDEVY

 
SGX sees share buyback boom: Why and what does it mean for investors?

2018-09-12 channelnewsasia
SINGAPORE: Singapore-listed companies have been repurchasing more of their own shares this year, with stock buybacks hitting a near three-year high last month, and analysts think this trend could continue for the rest of 2018 amid a volatile market.
SPXCY UOVEF SPXCF C09 UOVEY CDEVF CDEVY U11 O39 S68

 
CapitaLand gets a 'buy' on active capital recycling and portfolio rebalancing

2018-08-23 theedgemarkets
SINGAPORE (Aug 23): CapitaLand’s recent acquisitions in Singapore and China show continued efforts to recycle capital and rebalance its portfolio mix, say analysts.
C09 CDEVF CDEVY

 
No catalysts in sight for CityDev as new housing initiatives threaten to curb buying sentiment: Jefferies

2018-08-21 theedgemarkets
SINGAPORE (Aug 21): Jefferies is reiterating its “hold” call on City Developments (CDL) with a price target of S$11, which is based on a 22% discount to a RNAV of S$14, with the view that there are no immediate catalysts for the stock.
C09 CDEVF CDEVY

 
CapitaLand-CDL JV secures prime site in Sengkang Central for S$777.8 mil

2018-08-16 theedgemarkets
SINGAPORE (Aug 16): CapitaLand and City Developments Limited (CDL) jointly announced that they, via a joint venture (JV), have secured a mixed-use residential and commercial site in Sengkang Central for S$777.78 million.
C09 CDEVF CDEVY

 
Singapore home sales soar in July on minute-to-midnight buying

2018-08-15 theedgemarkets
SINGAPORE (Aug 15): Private home sales in Singapore soared to the highest in 16 months in July as buyers rushed to snap up properties hours before curbs aimed at quelling speculation came into effect.
C09 CDEVF CDEVY

 
Singapore home sales soar in July on minute-to-midnight buying

2018-08-15 malaymail
SINGAPORE, Aug 15 — Private home sales in Singapore soared to the highest in 16 months in July as buyers rushed to snap up properties hours before curbs aimed at quelling speculation came into effect.
C09 CDEVF CDEVY

 
CityDev posts 79.5% rise in 2Q earnings to S$205m; expects residential sales to moderate

2018-08-10 theedgemarkets
SINGAPORE (Aug 10): City Developments (CDL) announced earnings of S$204.8 million for the 2Q ended June, up 79.5% from its 2Q17 earnings of S$114.1 million a year ago, backed by stronger sales recognition during the period under review.
C09 CDEVF CDEVY

 
Singapore curbs may make property a buy, says CapitaLand CEO

2018-08-08 theedgemarkets
SINGAPORE (Aug 8): Singapore’s latest round of property curbs are probably enough to cool the market, and may present buying opportunities, the head of the city-state’s biggest developer said.
C09 CDEVF CDEVY

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

CUSIP: 177797305